Business

Biogen faces tough questions over $56K-a-year price of newly approved Alzheimer’s drug – CNBC

Biogen on Tuesday faced tough questions from Wall Street analysts over the $56,000 annual cost of its newly approved Alzheimer’s drug, Aduhelm a price tag executives are calling “fair” and “responsib… [+3147 chars]

View The Article On: CNBC

Powered By NewsAPI.org

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

To Top